Lantheus Holdings, Inc.
LNTHDrugs in Pipeline
9
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
7wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
DEFINITY
Cardiac Disease
Flurpiridaz F18
Coronary Artery Disease
DEFINITY®
Cardiac Disease
Sestamibi
Kawasaki Disease
Florbetaben (BAY94-9172)
Alzheimer Disease
LNTH2403 Phase 1 dose
Relapsed / Refractory Osteosarcoma
Peflutren Lipid Microsphere Injectable Suspension
Liver Disease
Technetium Tc99m Sestamibi
Kawasaki Disease
BMS747158
Ischemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DEFINITY | Phase 3 | Cardiac Disease | - | - |
Flurpiridaz F18 | Phase 3 | Coronary Artery Disease | - | - |
DEFINITY® | Phase 3 | Cardiac Disease | - | - |
Sestamibi | Phase 3 | Kawasaki Disease | - | - |
Florbetaben (BAY94-9172) | Phase 3 | Alzheimer Disease | - | - |
LNTH2403 Phase 1 dose | Phase 2 | Relapsed / Refractory Osteosarcoma | - | - |
Peflutren Lipid Microsphere Injectable Suspension | Phase 2 | Liver Disease | - | - |
Technetium Tc99m Sestamibi | Phase 2 | Kawasaki Disease | - | - |
BMS747158 | Phase 2 | Ischemia | - | - |